Neglected Tropical Diseases Diagnosis Market Valuation to Surpass US$ 10 Bn by 2032, Highlights Persistence Market Research

The global neglected tropical diseases (NTDs) diagnosis market is poised for significant growth in the coming years. It is projected to reach a market size of USD 10,204.8 million by 2032, up from USD 7,600 million in 2025. The market is anticipated to expand at a compound annual growth rate (CAGR) of approximately 4.3% between 2025 and 2032, driven by increased funding, technological advancements, and greater recognition of the burden posed by NTDs in underserved regions.

NTDs, which disproportionately affect impoverished populations, often remain underdiagnosed due to limited access to diagnostic tools and the complexity of their detection. The development of rapid, field-adapted diagnostic methods has been identified as a critical step toward managing and eliminating these diseases. As governments, international organizations, and research entities ramp up efforts to address this neglected area, the market for NTD diagnostic solutions is expected to see significant expansion.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35377

Key Industry Highlights

Market Growth and Size: The NTD diagnosis market is expected to grow from USD 7,600 million in 2025 to USD 10,204.8 million by 2032, reflecting a solid CAGR of 4.3%.

Geographical Insights: The Asia Pacific region is expected to maintain a dominant share in the market, largely due to ongoing government initiatives aimed at the elimination of NTDs.

Disease Prevalence: Soil-transmitted helminths are expected to account for the largest market share in 2025 due to the resurgence of infections, exacerbated by climate change.

Technological Developments: Advancements in multiplex assays and point-of-care diagnostics are anticipated to revolutionize the NTD diagnostics landscape.

Funding for NTD Control: The global focus on eliminating NTDs, including increased investments from organizations like the Global Health Innovative Technology (GHIT) Fund, will continue to drive the market forward.

Market Dynamics

Driver - National Programs Bolstering Early Detection and Mapping of NTDs

Government initiatives to enhance early detection and disease mapping are a key driver of market growth. For instance, India's Ministry of Health enhanced its Kala-Azar elimination campaign in 2023 by deploying mobile diagnostic units equipped with geo-tagging and rapid diagnostic tests (RDTs). These mobile units led to a 35% increase in case detection, particularly in endemic areas like Jharkhand and Bihar. Similarly, Ethiopia's integrated NTD master plan introduced multiplex immunoassay platforms that allow community-based surveys to test for multiple diseases simultaneously. Such initiatives, particularly in resource-poor settings, play a pivotal role in improving diagnostic capabilities and eliminating NTDs.

Restraint - Resource Constraints and Conflict Disrupting Market Progress

Despite these positive developments, the market faces several challenges, particularly in conflict zones and regions with inadequate healthcare infrastructure. In countries like Sudan, ongoing conflicts in 2023 led to the suspension of NTD surveillance programs as laboratory facilities were repurposed for emergency care. Moreover, a severe shortage of trained diagnostic personnel in rural health centers compounds the issue. A WHO-supported 2024 study in Mozambique found that over 60% of rural health posts lacked staff trained in basic diagnostic procedures, undermining efforts to combat NTDs.

Opportunity - Innovation in Molecular Tests and Artificial Intelligence (AI)

The growing focus on field-adapted molecular diagnostic tests and the application of AI to analyze diagnostic data present new opportunities in the market. The London School of Hygiene & Tropical Medicine's development of a battery-operated handheld PCR device for detecting Leishmania donovani DNA is an excellent example. The device has shown promise in increasing early case detection by 40%, facilitating timely interventions. Additionally, AI-powered tools, such as smartphone apps developed by the African Research Consortium for diagnosing schistosomiasis, are helping community health workers conduct accurate screenings in remote areas. These technological innovations are expected to improve diagnostic coverage and drive market growth.

Read More Related Reports: https://www.persistencemarketresearch.com/market-research/neglected-tropical-diseases-diagnosis-market.asp

Category-Wise Analysis

Disease Insights

The NTD diagnosis market is categorized based on the specific diseases being diagnosed, including dengue, rabies, yaws, chikungunya, leprosy, lymphatic filariasis, and soil-transmitted helminths, among others. Among these, soil-transmitted helminths are expected to account for 23.4% of the market share in 2025, driven by a shift from mass drug administration (MDA) campaigns to more targeted diagnostic-led interventions. Other diseases like dracunculiasis are expected to show steady growth as efforts to eliminate the disease intensify, particularly in countries like Mali, South Sudan, and Chad.

Diagnostic Method Type Insights

The NTD diagnostic market is further segmented based on diagnostic methods, including conventional methods and molecular/modern diagnostics. Conventional methods, such as microscopy, are expected to hold a dominant share of the market in 2025, primarily due to their low cost, ease of use, and compatibility with resource-limited settings. However, molecular methods, including PCR and Loop-Mediated Isothermal Amplification (LAMP), are anticipated to experience higher growth rates due to their ability to detect asymptomatic infections that conventional methods often miss.

Regional Insights

North America

While NTDs are often overlooked in mainstream healthcare settings in North America, certain conditions such as toxocariasis, cysticercosis, and Chagas disease are prevalent among underserved populations. The U.S. NTD diagnosis market is expected to grow significantly, with an increased focus on enhancing diagnostic infrastructure. For instance, Baylor College of Medicine has introduced a mobile outreach program in Texas and Arizona to perform point-of-care screening for strongyloidiasis and Chagas disease. These efforts reflect the growing recognition of the importance of NTD diagnostics in the U.S.

Middle East and Africa

In Africa, a significant portion of NTD diagnostics is decentralized, with community health workers and mobile health units playing a key role in disease detection. Countries like Ethiopia and Uganda have adopted point-of-care diagnostic methods, which have proven effective in detecting lymphatic filariasis and schistosomiasis. Innovation in diagnostics is also occurring at the local level, with Senegal's Institut Pasteur launching a solar-powered molecular diagnostic unit for human African trypanosomiasis and leishmaniasis. These localized solutions are expected to improve diagnostic sensitivity and reduce reliance on imported tests.

Asia Pacific

Asia Pacific is expected to hold a major share of the NTD diagnosis market in 2025, accounting for approximately 32.7% of the total market. This is due to ongoing efforts to integrate NTD screening into national health programs, particularly in countries like Vietnam and Thailand. Additionally, Southeast Asia has seen significant cross-border collaboration on NTD surveillance, particularly in the Mekong River basin. A 2024 initiative involving Thailand, Cambodia, and Laos piloted a shared digital diagnostic reporting platform for schistosomiasis, demonstrating the growing trend of regional cooperation in NTD control.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35377

Competitive Landscape

The NTD diagnosis market remains relatively fragmented and underfunded, with a limited number of companies focused on disease-specific diagnostics due to low commercial returns. Much of the market growth is being driven by public-private partnerships, academic collaborations, and non-profit organizations. However, diagnostic innovation is emerging from research institutions, particularly in Southeast Asia and Africa, which are developing localized solutions to meet the unique challenges posed by environmental conditions and healthcare infrastructure.

Key Industry Developments

March 2025: The GHIT Fund in Japan announced an investment of USD 11.4 million in five projects to develop drugs and diagnostics for schistosomiasis and other NTDs.

December 2024: The GHIT Fund and WHO signed an agreement to expand their collaboration on NTD diagnostics, ensuring broader access to affordable and effective diagnostic tools in endemic regions.

Key Players:
Key players in the NTD diagnostics market include:

F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Abbott Laboratories
Genome Diagnostics Pvt. Ltd.
InBios International, Inc.
ZeptoMetrix
Oscar Medicare Pvt Ltd.
Coris BioConcept
Omega Diagnostics Group PLC

Market Segmentation

The market is segmented based on:

Disease Type: Soil-transmitted helminths, schistosomiasis, lymphatic filariasis, leishmaniasis, and other NTDs.
Diagnostic Method: Conventional (microscopy, serology) vs. Molecular (PCR, LAMP, RDT).
Region: North America, Europe, Asia Pacific, Middle East, and Africa.

Recent Developments and Future Outlook

Recent developments in the NTD diagnosis market, particularly in the area of molecular diagnostics and point-of-care technologies, have increased the accuracy and efficiency of disease detection. The future outlook for the NTD diagnostics market looks promising, driven by continued advancements in diagnostic technology, greater global investment, and enhanced international collaborations aimed at eliminating these diseases. The next few years are expected to witness the increased commercialization of novel diagnostic tools that cater specifically to low-resource settings.

Read More Related Reports:

Dermal Allograft Market https://www.persistencemarketresearch.com/market-research/dermal-allograft-market.asp
Dural Graft Market https://www.persistencemarketresearch.com/market-research/dural-graft-market.asp
Sleep Aid Devices Market https://www.persistencemarketresearch.com/market-research/sleep-aid-devices-market.asp
Humanized Liver Mice Model Market https://www.persistencemarketresearch.com/market-research/humanized-liver-mice-model-market.asp
Aneurysm Clips Market https://www.persistencemarketresearch.com/market-research/aneurysm-clips-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.